How to offer Epithalon at your business
Learn what Epithalon is, where it stands under HHS's interim policy, and how to build an Epithalon offering that meets the policy's conditions.
This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.
If you’re researching how to offer Epithalon at your business or how to offer Epithalon through a clinical program, HHS’s interim enforcement discretion policy now includes Epithalon acetate for 503A compounding when specific conditions are met.
For clinics considering an Epithalon offering, the policy creates a potential pathway for patient-specific compounding, but it also comes with specific requirements. Your clinical protocols, pharmacy relationship, and dispensing workflows will need to account for the policy’s restrictions, including its requirement for intermittent courses.
Here’s what to know before adding it to your services.
What is Epithalon?
What is Epithalon?
Epithalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed from research on Epithalamin, an extract of the pineal gland.2,3
What the research shows
Much of the research on Epithalamin and epitalon has come from a single research group in St. Petersburg, Russia, over several decades, and independent replication is limited.2,3 Some of the findings in that literature, including a reported human cohort, involve Epithalamin or Epithalamin combined with a thymus peptide, not synthetic epitalon, and should not be read as findings about epitalon itself.¹⁴
A 2025 laboratory study reported effects on telomere length and telomerase-related measures in cultured human cell lines, including breast cancer cell lines, treated with Epithalon.4 That work was done in cells, not patients, and does not show that epitalon affects telomeres or health outcomes in people. The article has since been corrected by the publisher, and readers should consult the correction notice.5
FDA’s briefing document raised a theoretical concern about cancer risk related to telomerase activation, and FDA reported finding no human safety studies of epitalon.1,6
Why businesses are adding Epithalon
Interest in peptides is growing alongside broader attention to longevity and healthy aging services. Google Ads Keyword Planner data shows a 398% year-over-year increase in searches for “peptides” between June 2025 and July 2026.
That figure reflects interest in peptides overall. Interest in Epithalon itself is rising too: searches for “Epitalon peptide” (a common alternate spelling) grew about 300% year over year between November 2025 and November 2026 according to Google Trends. Search volume reflects curiosity, not understanding or evidence.
Is Epithalon legal to offer?
Epithalon falls within HHS’s interim enforcement discretion policy for 503A compounding when all specified conditions are met. The policy is nonbinding. It does not mean Epithalon is FDA-approved, establish a safe harbor, or add the substance to the 503A Bulks List. Epithalon is also not classified as Category 1.
HHS’s policy is an interim policy, meaning it may narrow, change, or be withdrawn at any point, and state requirements still apply. Review the HHS interim peptide policy breakdown before deciding whether your business can support an offering.
What forms of Epithalon does the policy cover?
The policy covers specific forms and conditions:
- Form: Epithalon acetate only. Other forms fall outside the policy.
- Routes: Subcutaneous or intramuscular injection only. Oral, intranasal, and other routes are not covered.
- Dispensing: Epithalon must be dispensed in intermittent courses.
- Formulations: Each compounded product may contain only one covered peptide. Blends and combinations fall outside the policy.
These restrictions should shape your clinical protocols, pharmacy discussions, and patient workflows from the start.
How to offer Epithalon at your business
Adding Epithalon requires a clinician-led program with pharmacy and operational processes that meet the policy’s conditions. Use these steps to assess whether your business is ready.
Step 1: Decide where Epithalon fits
Epithalon should fit a defined clinical service. If you’re planning to offer multiple peptide therapies, you’ll also need to consider how each fits your clinical services, prescribing workflows, pharmacy relationships, and patient care processes.
Start by evaluating three things:
- Patient demand: Is there a clear audience for this service?
- Clinical capacity: Do you have access to licensed clinicians who can evaluate patients, determine whether prescribing is appropriate, and oversee care?
- Brand fit: Can you explain the service accurately without making claims about outcomes that the evidence does not establish?
If you’re building a broader longevity offering, learn how to start a longevity clinic.
Step 2: Choose your care delivery model
In-person vs. hybrid vs. virtual
Decide whether the service will be in person, virtual, or hybrid. Your model affects how patients access consultations, prescriptions, administration, and follow-up.
It also determines certain regulatory requirements. Multi-state virtual care requires clinicians licensed in each state where patients are treated, along with alignment to applicable state compounding requirements.
Because the policy covers injectable forms only, your model needs a plan for administration:
- Virtual: Patient self-administration training, with clear written instructions and a fast way to answer questions after the first dose
- In person or hybrid: Determine whether in-clinic administration is an option and how it fits your scheduling capacity
Step 3: Build the clinical and regulatory foundation
Before accepting patients, establish who is responsible for clinical decisions and how the program will operate.
At a minimum, define:
- Which licensed clinicians can evaluate patients and prescribe
- How the pharmacy receives a valid, patient-specific prescription for each patient
- How clinical rationale and prescribing decisions are documented
- Which supervision and practice requirements apply in each state
- How patient eligibility, consent, documentation, and follow-up are handled
Prescribing decisions should remain within the discretion and clinical judgment of the treating clinician, based on the patient’s health and individual circumstances.
Step 4: Vet your pharmacy partner
Work with a state-licensed 503A compounding pharmacy and confirm it can meet the policy’s specific requirements. Ask about:
- Epithalon form: The pharmacy compounds Epithalon acetate only, not other forms.
- COA documentation: The bulk substance has a valid certificate of analysis (COA) documenting identity, purity, potency, and testing for relevant contaminants.
- Supplier validation: The bulk substance comes from an FDA-registered establishment. If the pharmacy sources it through a repacker, relabeler, or reseller, ask how the original manufacturer and COA are validated.
- Compounding standards: The pharmacy follows applicable USP standards, including USP Chapter 797 for sterile compounding, and maintains controls to prevent insanitary conditions.
- Product restrictions: Each compounded product contains only one covered peptide. Epithalon combinations with other peptides fall outside the policy.
- Course-based dispensing: Confirm that the pharmacy can support dispensing in intermittent courses and coordinate the quantity and timing of each course with the prescribing clinician. Workflows should not allow automatic, open-ended refills.
- Reporting and labeling: The pharmacy understands applicable reporting obligations for compounded products, serious adverse events, and product quality issues, as well as required patient labeling.
- State requirements: Confirm the pharmacy has the authority and licensure required to compound and dispense in each state where it operates.
Research-use-only peptides are not appropriate for patient care. Verify the pharmacy’s sourcing, manufacturer registration, and documentation rather than relying on a supplier’s marketing claims.
If you’re evaluating potential partners, understanding how 503A compounding pharmacies work can help you ask more informed questions.
Step 5: Standardize the care journey
Create a consistent process from the first inquiry through follow-up. Include patient intake and screening, clinician evaluation, informed consent, prescription coordination, administration or self-injection education, and follow-up.
Patients should understand that compounded Epithalon is not FDA-approved. Give them clear instructions for reporting side effects or injection-site concerns, and establish how your team will respond when an issue arises.
Build the policy’s intermittent-course requirement into the care journey:
- Course length: Define how the prescribing clinician determines and documents the length of each course.
- Breaks between courses: Establish how the required intervals or “washout” periods between courses are handled in the clinical protocol and dispensing workflow.
- Re-evaluation: Require clinical review before another course is prescribed. Don’t treat the service as an automatic refill program.
Step 6: Set up the technology
Your systems should support intake, clinical documentation, secure patient messaging, pharmacy coordination, and follow-up. Make sure refill workflows reflect the intermittent-course requirement and do not allow automatic, open-ended refills.
Step 7: Plan for policy changes
HHS’s policy is interim and may be revised or withdrawn. Monitor FDA and HHS updates, including formal rulemaking related to the 503A Bulks List.
Have a plan for communicating changes to patients and adjusting your operations if the policy’s conditions change or Epithalon is no longer covered.
Work to add peptides to your business faster with OpenLoop
Building a peptide program takes more than finding a pharmacy. OpenLoop® offers infrastructure to help businesses develop and operate peptide services, including:
- 503A pharmacy partners where permitted by law
- Medically reviewed protocols
- A 50 state clinical network
- Operational support designed to help clients meet applicable requirements
- 24/7/365 patient support
Contact OpenLoop to discuss your business and program needs.
Compounded medications are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality. Prescriptions are issued following evaluation by a licensed healthcare provider only when clinically appropriate. The peptides discussed in this article have not been approved by FDA for recovery or performance. Compounded preparations require a prescription following an appropriate clinical evaluation, and no prescription is guaranteed. Availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies.
References
- U.S. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (introduction and substance-specific briefing documents). https://www.fda.gov/media/193342/download
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID 15452611. https://pubmed.ncbi.nlm.nih.gov/15452611/
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682. https://pubmed.ncbi.nlm.nih.gov/12937682/
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. https://pubmed.ncbi.nlm.nih.gov/40908429/
- Correction to: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025 Nov 15;27(1):1. PMID 41240216. https://pubmed.ncbi.nlm.nih.gov/41240216/
- Drug Topics. FDA panel to evaluate 7 popular peptides for compounding substances list (summary of FDA briefing documents). https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
